4.245 USD
-0.01 (-0.35%)
LPCN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While LPCN seems to be doing ok healthwise, there are quite some concerns on its profitability. LPCN is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year LPCN was profitable.
In the past year LPCN has reported a negative cash flow from operations.
LPCN had negative earnings in 4 of the past 5 years.
LPCN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -34.06%, LPCN perfoms like the industry average, outperforming 47.92% of the companies in the same industry.
Looking at the Return On Equity, with a value of -38.72%, LPCN is in line with its industry, outperforming 57.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.06% | ||
| ROE | -38.72% | ||
| ROIC | N/A |
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LPCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LPCN has more shares outstanding than it did 1 year ago.
LPCN has more shares outstanding than it did 5 years ago.
LPCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
LPCN has an Altman-Z score of -10.67. This is a bad value and indicates that LPCN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.67, LPCN is doing worse than 74.48% of the companies in the same industry.
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.67 |
ROIC/WACCN/A
WACC9.4%
2.3 Liquidity
A Current Ratio of 8.25 indicates that LPCN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.25, LPCN is in the better half of the industry, outperforming 74.48% of the companies in the same industry.
LPCN has a Quick Ratio of 8.25. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.25, LPCN is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.25 | ||
| Quick Ratio | 8.25 |
3. Growth
3.1 Past
LPCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 168.92%, which is quite impressive.
LPCN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 213.46% yearly.
LPCN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -45.44%.
Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 133.89% on average per year.
EPS 1Y (TTM)168.92%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%-43.9%
Revenue 1Y (TTM)-45.44%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -39.17% on average over the next years. This is quite bad
Based on estimates for the next years, LPCN will show a very strong growth in Revenue. The Revenue will grow by 37.92% on average per year.
EPS Next Y-230.15%
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
EPS Next 5YN/A
Revenue Next Year-90.82%
Revenue Next 2Y-75.39%
Revenue Next 3Y-14.08%
Revenue Next 5Y37.92%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.32 indicates a reasonable valuation of LPCN.
92.71% of the companies in the same industry are more expensive than LPCN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.61. LPCN is valued rather cheaply when compared to this.
LPCN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.32 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as LPCN's earnings are expected to decrease with -39.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
5. Dividend
5.1 Amount
No dividends for LPCN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:LPCN (12/23/2025, 3:26:08 PM)
4.245
-0.01 (-0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.59%
Inst Owner Change0.18%
Ins Owners2.84%
Ins Owner Change0%
Market Cap23.56M
Revenue(TTM)4.32M
Net Income(TTM)-5.48M
Analysts82.5
Price Target7.01 (65.14%)
Short Float %2.14%
Short Ratio2.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.8%
Min EPS beat(2)-7.12%
Max EPS beat(2)-0.49%
EPS beat(4)2
Avg EPS beat(4)137.56%
Min EPS beat(4)-7.12%
Max EPS beat(4)555.88%
EPS beat(8)6
Avg EPS beat(8)100.41%
EPS beat(12)7
Avg EPS beat(12)53.04%
EPS beat(16)10
Avg EPS beat(16)134.32%
Revenue beat(2)1
Avg Revenue beat(2)57.05%
Min Revenue beat(2)-52.63%
Max Revenue beat(2)166.72%
Revenue beat(4)2
Avg Revenue beat(4)17.73%
Min Revenue beat(4)-74.1%
Max Revenue beat(4)166.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.78%
PT rev (3m)-6.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.91%
EPS NY rev (1m)-5.93%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-51.87%
Revenue NQ rev (3m)-51.87%
Revenue NY rev (1m)-20.76%
Revenue NY rev (3m)-20.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.32 | ||
| Fwd PE | N/A | ||
| P/S | 5.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.67 | ||
| P/tB | 1.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.51
EY12.01%
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.78
BVpS2.55
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.06% | ||
| ROE | -38.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.25 | ||
| Quick Ratio | 8.25 | ||
| Altman-Z | -10.67 |
F-Score2
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)521.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.92%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%-43.9%
EPS Next Y-230.15%
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-45.44%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A
Revenue Next Year-90.82%
Revenue Next 2Y-75.39%
Revenue Next 3Y-14.08%
Revenue Next 5Y37.92%
EBIT growth 1Y-19.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.97%
OCF growth 3YN/A
OCF growth 5YN/A
LIPOCINE INC / LPCN FAQ
What is the ChartMill fundamental rating of LIPOCINE INC (LPCN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to LPCN.
Can you provide the valuation status for LIPOCINE INC?
ChartMill assigns a valuation rating of 2 / 10 to LIPOCINE INC (LPCN). This can be considered as Overvalued.
What is the profitability of LPCN stock?
LIPOCINE INC (LPCN) has a profitability rating of 1 / 10.
Can you provide the financial health for LPCN stock?
The financial health rating of LIPOCINE INC (LPCN) is 6 / 10.
What is the expected EPS growth for LIPOCINE INC (LPCN) stock?
The Earnings per Share (EPS) of LIPOCINE INC (LPCN) is expected to decline by -230.15% in the next year.